• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation.根治性放化疗治疗食管癌患者的失败模式。
Cancer. 2012 May 15;118(10):2632-40. doi: 10.1002/cncr.26586. Epub 2011 Oct 5.
2
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer.局部晚期食管癌根治性放化疗后与局部区域失败相关的因素。
Ann Surg Oncol. 2014 Jan;21(1):306-14. doi: 10.1245/s10434-013-3303-0. Epub 2013 Nov 7.
3
Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era.现代时代食管癌确定性放化疗后腹腔干节点失败模式。
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e231-9. doi: 10.1016/j.ijrobp.2011.12.061. Epub 2012 Mar 19.
4
Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer.新辅助放化疗后放疗靶区外的残留肿瘤:食管癌生存的新预后因素。
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):845-52. doi: 10.1016/j.ijrobp.2013.11.009. Epub 2014 Jan 8.
5
Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation.局部控制可能是改善接受同步放化疗的食管鳞状细胞癌治疗效果的关键。
Digestion. 2014;90(4):254-60. doi: 10.1159/000368983. Epub 2014 Dec 19.
6
(18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy.基于18F-氟脱氧葡萄糖正电子发射断层扫描对接受根治性放疗的非小细胞肺癌局部失败模式的评估
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1397-402. doi: 10.1016/j.ijrobp.2007.08.052.
7
Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.总肿瘤糖酵解评估鉴定出接受根治性放化疗的食管腺癌患者中具有高治愈率的患者亚群。
Ann Surg. 2020 Aug;272(2):311-318. doi: 10.1097/SLA.0000000000003228.
8
Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.局部晚期食管癌同步加量调强放疗的局部控制和毒性:前瞻性 I/II 期试验的中期结果。
J Thorac Oncol. 2017 Feb;12(2):375-382. doi: 10.1016/j.jtho.2016.10.013. Epub 2016 Oct 26.
9
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.局部区域食管鳞癌根治性放化疗中的累及野照射:来自 ESO-Shanghai 1 试验的结果。
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1396-1406. doi: 10.1016/j.ijrobp.2021.02.053. Epub 2021 Mar 5.
10
Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.正电子发射断层扫描指导下的放化疗治疗食管鳞癌:正电子发射断层扫描无应答者中改变化疗方案无益。
J Thorac Oncol. 2019 Mar;14(3):540-546. doi: 10.1016/j.jtho.2018.10.152. Epub 2018 Nov 1.

引用本文的文献

1
Prognostic Impact of Thoracic Extra-regional Lymph Node Metastasis Defined By the 12th Japanese Classification Following Definitive Radiotherapy for Esophageal Squamous Cell Carcinoma.日本第12版分类法定义的胸段区域外淋巴结转移对食管鳞状细胞癌根治性放疗后预后的影响
J Gastrointest Cancer. 2025 Jun 14;56(1):136. doi: 10.1007/s12029-025-01258-0.
2
A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study.紫杉醇脂质体联合放化疗联合或不联合重组人血管内皮抑制素治疗不可切除食管鳞状细胞癌的生存结果比较:一项回顾性研究。
Discov Oncol. 2025 May 26;16(1):925. doi: 10.1007/s12672-025-02711-z.
3
Late course adaptive radiotherapy based on tumor volume reduction decreases Gastrointestinal toxicity for abdominal lymph node metastasis of hepatocellular carcinoma.基于肿瘤体积缩小的晚期自适应放疗可降低肝细胞癌腹部淋巴结转移的胃肠道毒性。
Sci Rep. 2025 May 20;15(1):17477. doi: 10.1038/s41598-025-02363-7.
4
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study.确定性放化疗联合抗程序性死亡受体1(PD-1)免疫疗法治疗不可切除食管鳞状细胞癌:一项多中心真实世界研究
Cancer Biol Ther. 2025 Dec;26(1):2504726. doi: 10.1080/15384047.2025.2504726. Epub 2025 May 14.
5
Consolidation Chemotherapy Provided Survival Benefit for Esophageal Squamous Cell Carcinoma Patients Who Underwent Concurrent Chemoradiotherapy Lower Than 60 Gy.巩固化疗为接受低于60Gy同步放化疗的食管鳞状细胞癌患者带来生存获益。
Thorac Cancer. 2025 Apr;16(7):e70012. doi: 10.1111/1759-7714.70012.
6
Constructing individualized follow-up strategies for locally advanced esophageal squamous cell carcinoma patients based on dynamic recurrence risk changes.基于动态复发风险变化为局部晚期食管鳞状细胞癌患者构建个体化随访策略。
Sci Rep. 2025 Jan 2;15(1):175. doi: 10.1038/s41598-024-84099-4.
7
A CT-based subregional radiomics nomogram for predicting local recurrence-free survival in esophageal squamous cell cancer patients treated by definitive chemoradiotherapy: a multicenter study.基于CT的亚区域影像组学列线图预测接受根治性放化疗的食管鳞状细胞癌患者的无局部复发生存率:一项多中心研究
J Transl Med. 2024 Dec 5;22(1):1108. doi: 10.1186/s12967-024-05897-y.
8
Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study.局部晚期可切除或不可切除食管鳞癌患者采用新辅助化疗放疗联合nab-紫杉醇加顺铂治疗的 I/II 期前瞻性队列研究。
Strahlenther Onkol. 2024 Dec;200(12):1038-1046. doi: 10.1007/s00066-024-02286-8. Epub 2024 Aug 12.
9
Tumor-Derived Exosomal miR-143-3p Induces Macrophage M2 Polarization to Cause Radiation Resistance in Locally Advanced Esophageal Squamous Cell Carcinoma.肿瘤来源的外泌体 miR-143-3p 诱导巨噬细胞 M2 极化导致局部晚期食管鳞癌的放射抵抗。
Int J Mol Sci. 2024 May 31;25(11):6082. doi: 10.3390/ijms25116082.
10
Long-term clinical outcomes and prognosis after definitive radiotherapy for patients with cervical esophageal squamous cell carcinoma: a single-institution retrospective study.颈段食管鳞状细胞癌患者根治性放疗后的长期临床结局和预后:一项单机构回顾性研究
J Thorac Dis. 2023 Dec 30;15(12):6976-6987. doi: 10.21037/jtd-23-1789. Epub 2023 Dec 22.

本文引用的文献

1
Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.强度调制质子治疗进一步降低局部晚期远端食管肿瘤根治性治疗中正常组织的照射量:一项剂量学研究。
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1336-42. doi: 10.1016/j.ijrobp.2010.07.2001. Epub 2011 Apr 4.
2
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.高剂量质子治疗联合化疗治疗不可切除的 III 期非小细胞肺癌的 II 期研究。
Cancer. 2011 Oct 15;117(20):4707-13. doi: 10.1002/cncr.26080. Epub 2011 Mar 22.
3
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
4
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.多西他赛/顺铂/氟尿嘧啶诱导化疗治疗淋巴结阳性食管癌患者。
Digestion. 2011;83(3):146-52. doi: 10.1159/000321797. Epub 2011 Jan 21.
5
Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.早期、医学上无法手术的非小细胞肺癌的自适应/消融质子治疗的毒性和失败模式。
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1350-7. doi: 10.1016/j.ijrobp.2010.04.049. Epub 2011 Jan 20.
6
Esophageal cancer dose escalation using a simultaneous integrated boost technique.食管癌采用同步整合升压技术进行剂量递增。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):468-74. doi: 10.1016/j.ijrobp.2010.10.023. Epub 2010 Dec 1.
7
A treatment planning comparison between proton beam therapy and intensity-modulated x-ray therapy for recurrent nasopharyngeal carcinoma.质子束治疗与调强适形放疗治疗复发性鼻咽癌的计划比较。
J Xray Sci Technol. 2010;18(4):443-50. doi: 10.3233/XST-2010-0265.
8
Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer.磷酸肌醇 3 激酶、丝裂原活化蛋白激酶和刺猬信号通路之间的交叉信号在食管癌中存在。
Int J Cancer. 2011 Jul 15;129(2):275-84. doi: 10.1002/ijc.25673. Epub 2010 Nov 3.
9
Intensity modulated proton therapy treatment planning using single-field optimization: the impact of monitor unit constraints on plan quality.采用单野优化的强度调制质子治疗计划:监测单位约束对计划质量的影响。
Med Phys. 2010 Mar;37(3):1210-9. doi: 10.1118/1.3314073.
10
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).西妥昔单抗联合顺铂和多西他赛治疗未经治疗的晚期胃或胃食管交界腺癌患者的II期研究(DOCETUX研究)
Br J Cancer. 2009 Oct 20;101(8):1261-8. doi: 10.1038/sj.bjc.6605319. Epub 2009 Sep 22.

根治性放化疗治疗食管癌患者的失败模式。

Failure patterns in patients with esophageal cancer treated with definitive chemoradiation.

机构信息

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Cancer. 2012 May 15;118(10):2632-40. doi: 10.1002/cncr.26586. Epub 2011 Oct 5.

DOI:10.1002/cncr.26586
PMID:22565611
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3747650/
Abstract

BACKGROUND

Local failure after definitive chemoradiation therapy for unresectable esophageal cancer remains problematic. Little is known about the failure pattern based on modern-day radiation treatment volumes. We hypothesized that most local failures would be within the gross tumor volume (GTV), where the bulk of the tumor burden resides.

METHODS

We reviewed treatment volumes for 239 patients who underwent definitive chemoradiation therapy and compared this information with failure patterns on follow-up positron emission tomography (PET). Failures were categorized as within the GTV, the larger clinical target volume (CTV, which encompasses microscopic disease), or the still larger planning target volume (PTV, which encompasses setup variability) or outside the radiation field.

RESULTS

At a median follow-up time of 52.6 months (95% confidence interval, 46.1-56.7 months), 119 patients (50%) had experienced local failure, 114 (48%) had distant failure, and 74 (31%) had no evidence of failure. Of all local failures, 107 (90%) were within the GTV, 27 (23%) were within the CTV, and 14 (12%) were within in the PTV. On multivariate analysis, GTV failure was associated with tumor status (T3/T4 vs T1/T2; odds ratio, 6.35; P = .002), change in standardized uptake value on PET before and after treatment (decrease >52%: odds ratio, 0.368; P = .003), and tumor size (>8 cm, 4.08; P = .009).

CONCLUSIONS

Most local failures after definitive chemoradiation for unresectable esophageal cancer occur in the GTV. Future therapeutic strategies should focus on enhancing local control.

摘要

背景

不可切除食管癌根治性放化疗后局部失败仍然是个问题。基于现代放射治疗体积,我们对失败模式知之甚少。我们假设大多数局部失败将发生在大体肿瘤体积(GTV)内,那里是肿瘤负荷的主要部位。

方法

我们回顾了 239 例接受根治性放化疗的患者的治疗体积,并将这些信息与随访正电子发射断层扫描(PET)的失败模式进行了比较。失败被分为 GTV 内、较大的临床靶区(CTV,包括显微镜下的疾病)或更大的计划靶区(PTV,包括设置变异性)或放疗野外。

结果

在中位随访时间为 52.6 个月(95%置信区间,46.1-56.7 个月)时,119 例患者(50%)发生了局部失败,114 例(48%)发生了远处失败,74 例(31%)没有失败的证据。所有局部失败中,107 例(90%)位于 GTV 内,27 例(23%)位于 CTV 内,14 例(12%)位于 PTV 内。多因素分析显示,GTV 失败与肿瘤状态(T3/T4 与 T1/T2;优势比,6.35;P =.002)、治疗前后 PET 标准化摄取值的变化(减少>52%:优势比,0.368;P =.003)和肿瘤大小(>8 cm,4.08;P =.009)有关。

结论

不可切除食管癌根治性放化疗后大多数局部失败发生在 GTV 内。未来的治疗策略应侧重于提高局部控制率。